Microfluidic news

Biomarkers for the prediction and prevention of brain disorders

First stage deadline : 19th September 2023

Elvesys – the ideal SME partner for your Horizon Europe consortium!

Elvesys is a French SME whose expertise includes microfluidic instrumentation and flow control systems for organ/tissue-on-chip systems and automated cell culture. We would be excited to support you in developing your in vitro model for fluid biomarker validation and to contribute our expertise in the elaboration and management of Horizon Europe projects under the call “Validation of biomarkers for the prediction and prevention of brain diseases”. Contact us to discuss your project idea!

Why should you use microfluidics for your biomarker-related experiments?

Organ-on-chip platforms can replicate human organs or tissues remarkably well
Perfusing your organ-on-chip device enables injection of media and drugs in programmed sequences
We develop automated tools that simplify researchers’ and pharmaceutical companies’ access to microfluidics technology
Microfluidics paves the way for less animal testing and more reproducible results for biomedical research

rebond-contact-documentation

Validation of fluid-derived biomarkers for the prediction and prevention of brain disorders

What can microfluidics do for the validation of biomarkers related to brain disorders?

Through microfluidic perfusion of the medium of your cell culture, you can obtain control of microphysiological conditions that closely resemble the real environment of cells in the human body. Controlled perfusion can add shear stress to the cell culture, which is necessary for cell maturation and differentiation. Pharmaceutically active compounds can be added to the in vitro cell culture with high precision, and samples can be taken continuously rather than just at specific time points. If necessary, you can observe the cells under the microscope and take images at any time. This way, the objectives of the call Validation of fluid-derived biomarkers for the prediction and prevention of brain disorders can be met in an innovative manner.

Development of new in vitro biomarker validation models for biomedical research

⇒ There is an urgent need to improve diagnosis, drug discovery, and the development pipeline to increase the success rate of new therapeutics (for cancer drugs it is only 3.4%) and enable earlier detection and treatment. Microfluidic cell-based assays and analyses are among the most promising strategies, supported by direct feedback from industry and regulatory authorities.

Organ- and tissue-on-chip systems in disease modeling

⇒ Animal testing is increasingly restricted by European regulations. Cell cultures on microfluidic chips allow the microenvironment of the cells to be reproduced very accurately, both in terms of the chemicals that come into contact with the cells and the physical parameters (temperature, shear stress on the cells, etc.). They are therefore much more meaningful human models than conventional cell cultures and are excellent candidates for replacing animal experiments in biomedical research.

rebond-contact-documentation

What we can do for the “Validation of fluid-derived biomarkers for the prediction and prevention of brain disorders” call, as an SME partner:

For this Horizon Europe call on biomarker validation, we can bring our expertise in microfluidic instrumentation and flow management to help you develop a dynamic cell culture or an organ-on-chip platform for your project that can be automatised and user-friendly.

Specifically, Elvesys can:

Support the development of novel in vitro models
Propose a user-friendly organ-on-chip system to recreate the human microphysiological environment
Automatize the fluid handling inside your system, including media perfusion and drug administration